A Phase 2, Open Label, Single Arm Trial of TPI 287 in Patients With Advanced, Unresectable Pancreatic Cancer After Prior Treatment With a Gemcitabine-Based Therapy.
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2014
At a glance
- Drugs TPI 287 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Cortice Biosciences
- 07 Jun 2017 Biomarkers information updated
- 05 Jun 2009 Planned end date changed from 1 Oct 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
- 05 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.